Pharsight

Targiniq patents expiration

TARGINIQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9073933 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(9 months from now)

US9522919 PURDUE PHARMA LP Oxycodone compositions
Mar, 2025

(9 months from now)

US7683072 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(9 months from now)

US7674800 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822487 PURDUE PHARMA LP Opioid agonist/opioid antagonist/acetaminophen combinations
Dec, 2018

(5 years ago)

US6696066 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US9205082 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US6277384 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US8673355 PURDUE PHARMA LP Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

US9474750 PURDUE PHARMA LP Opioid agonist/opioid antagonist/acetaminophen combinations
Dec, 2018

(5 years ago)

US9084729 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9283216 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9161937 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9511066 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US8969369 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9056051 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9283221 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9168252 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9345701 PURDUE PHARMA LP Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

US9907793 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(1 year, 2 months ago)

US9555000 PURDUE PHARMA LP Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(1 year, 2 months ago)

US8846090 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(1 year, 2 months ago)

US8846091 PURDUE PHARMA LP Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(1 year, 2 months ago)

US7674799 PURDUE PHARMA LP Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(9 months from now)

Targiniq is owned by Purdue Pharma Lp.

Targiniq contains Naloxone Hydrochloride; Oxycodone Hydrochloride.

Targiniq has a total of 24 drug patents out of which 19 drug patents have expired.

Expired drug patents of Targiniq are:

  • US8822487
  • US6696066
  • US9205082
  • US6277384
  • US8673355
  • US9474750
  • US9084729
  • US9283216
  • US9161937
  • US9511066
  • US8969369
  • US9056051
  • US9283221
  • US9168252
  • US9345701
  • US9907793
  • US9555000
  • US8846090
  • US8846091

Targiniq was authorised for market use on 23 July, 2014.

Targiniq is available in tablet, extended release;oral dosage forms.

Targiniq can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate by providing an abuse-deterrent oral controlled release combination drug product, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

The generics of Targiniq are possible to be released after 30 March, 2025.

Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient

Market Authorisation Date: 23 July, 2014

Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

TARGINIQ family patents

Family Patents